Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-22
2008-07-22
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C514S017400, C530S328000, C530S329000
Reexamination Certificate
active
10659053
ABSTRACT:
The present invention is directed to a composition and method for treating uro-genital conditions. One embodiment disclosed is a pharmaceutical composition for use in the treatment of uro-genital conditions wherein said composition comprises a KPV dimer, a first preservative agent, a solvent, an alkalizer, an acrylic acid-based polymer, a second preservative agent and a gelatinizing agent. Another embodiment of the invention is disclosed wherein the composition comprises CKPV (SEQ ID NO: 5) dimer, API, Carbopol®, NF, propylparaben, NF; methylparaben, NF; propylene glycol, USP; edetic acid (EDTA), USP; 2 M sodium hydroxide solution (NaOH); and sterile water for injection, USP. Also disclosed are methods and indications for use of the disclosed composition.
REFERENCES:
patent: 3247182 (1961-11-01), Schwyzer et al.
patent: 3300468 (1964-05-01), Schwyzer et al.
patent: 4837378 (1989-06-01), Borgman
patent: 4918055 (1990-04-01), Hruby et al.
patent: 5028592 (1991-07-01), Lipton
patent: 5157023 (1992-10-01), Lipton
patent: 5739111 (1998-04-01), Mahe
patent: 6001812 (1999-12-01), Mahe
patent: 6800291 (2004-10-01), Lipton et al.
patent: 6803044 (2004-10-01), Catania et al.
patent: 6894028 (2005-05-01), Lipton et al.
patent: 7115574 (2006-10-01), Catania et al.
patent: 7232804 (2007-06-01), Lipton et al.
patent: 2002/0146374 (2001-01-01), Lipton
patent: 2002/0183255 (2001-04-01), Lipton et al.
patent: 2002/0137685 (2001-09-01), Catania et al.
patent: 0335662 (1989-10-01), None
patent: 0972 522 (2000-01-01), None
patent: 2784028 (2000-04-01), None
patent: 59-021613 (1984-02-01), None
patent: 2-500361 (1990-02-01), None
patent: 06-345665 (1994-12-01), None
patent: 09-124502 (1997-05-01), None
patent: WO87/04623 (1987-03-01), None
patent: 88/00833 (1988-02-01), None
patent: WO93/01211 (1993-01-01), None
patent: WO97/10838 (1997-03-01), None
patent: WO99/58101 (1999-11-01), None
patent: PCT/US00/07846 (2000-03-01), None
patent: WO 00/42856 (2000-07-01), None
U.S. Appl. No. 09/533,341, filed Mar. 23, 2000, Anna P. Catania et al.
U.S. Appl. No. 09/957,765, filed Sep. 21, 2001, Anna P. Catania et al.
U.S. Appl. No. 60/200,287, filed Apr. 28, 2000, Lipton, J.M.
U.S. Appl. No. 09/774,282, filed Jan. 29, 2001, Lipton, J.M.
U.S. Appl. No. 09/828,272, filed Apr. 6, 2001, Lipton, J.M.
U.S. Appl. No. 09/704,327, filed Nov. 1, 2000, Lipton, J.M.
U.S. Appl. No. 09/535,066, filed Mar. 23, 2000, Lipton et al.
U.S. Appl. No. 10/420,578, filed Apr. 21, 2003, Lipton et al.
U.S. Appl. No. 10/426,647, filed Apr. 29, 2003, Lipton et al.
U.S. Appl. No. 10/298,142, filed Nov. 15, 2002, Lipton.
Airaghi, L., et al., “Elevated concentrations of plasma α-MSH are associated with reduced disease progression in HIV-infected patients,”J. Lab. Clin. Med. 1333(3) 309-315 (1999).
Airaghi L., et al., “Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy.”Am. Heart J. 130: 204-211, (1995).
Airaghi L., et al., “Plasma concentrations of α-melanocyte-stimulating hormone are elevated in patients on chronic haemodialysis,”Nephrology Dialysis Transplantation15:1212-1216, (2000).
Armstrong, “The Microbiology of the Eye.”Ophthal. Physiol. Opt. 20: 429-503 (2000).
Aylad et al., “Influence of Oral Acyclovir on Ocular Complications ofHerpes zoster ophthalmicus.” Eye8: 70-74 (1994).
Baker, M., et al., “The Relationship between Interleukin-6 and Herpes Simplex Virus Type-1: Implications for Behavior and Immunopathology,”Brain Behav. Immun. 13(3):201-11 (1999).
Baker, et al., “Principles of Ambulatory Medicine,”Williams and Wilkins(1982).
Barcellini, W., et al., “Inhibitory Influences of α-MSH peptides on HIV-1 expression in Monocytic cells,”12thWorld AIDS Conference Geneva, Abstract No. 60685, Jun. 28-Jul. 3, (1998).
Barcellini W., et al., “α-MSH peptides inhibit HIV-1 expression in chronically infected promonocytic U1 cells and in acutely infected monocytes,”Journal of Leukocyte Biology68:693-699, (2000).
Bhattacharya, A., et al., “Effect of Cyclic AMP on RNA and Protein Synthesis inCandida albicans,” Biochem, Biophysics. Res. Commun., 77: 1438-44 (1977).
Bickers, D., “Sun-Induced Disorders,”Emergency Medicine Clinics of North America, 3(4): 659-663, 660 (1985).
Capsoni, F., et al., “Effect of Corticosteriods on Neutrophil Function: Inhibition of Antibody-dependent Cell-Mediated Cytotoxicity (ADCC),”J. Immunopharmacol. 5, 217-30 (1983).
Cartledge, J.D., et al., “Clinically Significant Azole Cross-Resistance in Candida Isolates from HIV-Positive Patients with Oral Candidosis,”AIDS11:1839-44 (1997).
Catania, A., et al., “α-Melanocyte Stimulating Hormone in the Modulation of Host Reactions,”Endocr. Rev. 14, 564-576 (1993).
Catania, A., et al., “Melanocortin Peptides Inhibit Production of Proinflammatory Cytokines in Blood of HIV-Infected Patients,”Peptides, 19(6): 1099-1104 (1998).
Catania, A., et al., “The Neuropeptide α-MSH in HIV Infection and Other Disorders in Humans,”Ann. N.Y. Acad. Sci. 840: 848-856 (1998).
Catania, A., et al., “The Neuropeptide α-MSH has Specific Receptors on Neutrophils and Reduces Chemotaxis in Vitro,”Peptides17, 675-679 (1996).
Catania, A., et al., “a-MSH in normal human physiology and disease states,”Trends Endocrinol. Metab. 11:304-308, (2000).
Catania, A., et al., “a-MSH in systemic inflammation: central and peripheral actions,”Annals of the New York Academy of Sciences, 885:183-187, (1999).
Catania, A., et al., “Cytokine antagonists in infectious and inflammatory disorders,”Annals of the New York Academy of Sciences741: 149-161, (1994).
Catania, A., et al., “α-melanocyte-stimulating hormone peptides in host responses: from basic evidence to human research,”Annals of the New York Academy of Sciences680: 412-423, (1993).
Catania, A., et al., “Plasma concentrations and anti-L-cytokine effects of α-melanocyte stimulating hormone in septic patients,”Crit. Care Med. 28: 1403-1407, (2000).
Catania, A., et al., “Cytokine antagonists in aged subjects and their relation with cellular immunity,”Journal of Gerontology: Biological Sciences52A: B93-97, (1997).
Catania, A., et al., “Plasma concentration of cytokine antagonists in patients with HIV infection,”Neuroimmunomodulation1: 42-49, (1994).
Catania, A., et al., “Proopiomelanocortin-derived peptides and cytokines: relations in patients with acquired immunodeficiency syndrome,”Clinical Immunology and Immunopathology66: 73-79, (1993).
Cavello, J., et al., “Sunburn”,Dermatologic Clinics, 4(2): 181-187, 181 (1986).
Ceriani, G., et al., “Central Neurogenic Antiinflammatory Action of α-MSH: Modulation of Peripheral Inflammation Induced by Cytokines and other Mediators of Inflammation,”Neuroendocrinology, 59:138-143 (1994).
Ceriani, G., et al., “The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats,”Neuroimmunomodulation1:28-32, (1994).
Chiao, H., et al., “α-MSH reduces endotoxin-induced liver inflammation,”J. Clin. Invest. 97: 2038-2044, (1996).
Csata, M., et al., “Enhancement ofCandida albicanskilling activity of separated human epidermal cells by alpha-melanocyte stimulating hormone,”British Journal of Dermatology, 121(1) 145-147 (1989).
Cutuli, M., et al., “Antimicrobial effects of α-MSH peptides,”Journal of Leukocyte Biology67:233-239 (2000).
Deeter, L.B., et al., “Antipyretic Properties of Centrally Administered α-MSH Fragments in the Rabbit,”Peptides9, 1285-1288 (1989).
Delgado, R., et al., “Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia,”Journal of Leukocyte Biology, 63: 740-745 (1998).
Domk-Optiz,
Catania Anna P.
Lipton James M.
Dykema Gossett PLLC
Gupta Anish
MSH Pharma, Incorporated
Zinkl Gregory M.
LandOfFree
Composition and method of treatment for urogenital conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method of treatment for urogenital conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method of treatment for urogenital conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3936347